MedTrace Logo

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors

NCT03472352 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-03-21

No results posted yet for this study

Summary

This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

An anticancer medication (A01) and immune cells (IC01)

The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.

Sponsors & Collaborators

  • The Second People's Hospital of Yibin

    collaborator OTHER

  • Hangzhou Converd Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2019-04-30
Completion
2019-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472352 on ClinicalTrials.gov